Novartis AG
A global medicines company that researches, develops, and markets healthcare products.
NOVN | SW
Overview
Corporate Details
- ISIN(s):
- CH0012005267 (+10 more)
- LEI:
- 5493007HIVTX6SY6XD66
- Country:
- Switzerland
- Address:
- LICHTSTR. 35, 4056 BASEL
- Website:
- https://www.novartis.com/
- Sector:
- Manufacturing
Description
Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-05-16 08:00 |
Novartis announces changes to the Executive Committee
|
English | 21.1 KB | ||
| 2018-05-03 05:06 |
Sandoz receives complete response letter from the US FDA for proposed biosimila…
|
English | 16.9 KB | ||
| 2018-05-01 23:26 |
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receiv…
|
English | 32.5 KB | ||
| 2018-05-01 08:00 |
Novartis provides update on proposed acquisition of AveXis
|
English | 17.5 KB | ||
| 2018-04-19 08:15 |
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical O…
|
English | 18.5 KB | ||
| 2018-04-19 08:00 |
Novartis delivered a strong first quarter and acted to become a more focused me…
|
English | 84.4 KB | ||
| 2018-04-17 08:00 |
Novartis tender offer for AveXis commences
|
English | 18.9 KB | ||
| 2018-04-09 07:45 |
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform ca…
|
English | 26.6 KB | ||
| 2018-03-27 08:00 |
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 …
|
English | 19.9 KB | ||
| 2018-03-12 07:00 |
NOVARTIS FINANCE S.A. : Directorate change
|
English | 20.5 KB | ||
| 2018-02-01 22:05 |
Novartis completes subsequent offering period of the tender offer for Advanced …
|
English | 18.1 KB | ||
| 2018-01-26 19:02 |
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Trea…
|
English | 28.6 KB | ||
| 2018-01-24 19:02 |
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
|
English | 7.3 KB | ||
| 2018-01-24 07:00 |
Novartis delivered good operational performance and landmark innovation in 2017…
|
English | 119.3 KB | ||
| 2018-01-11 07:00 |
Novartis appoints Elizabeth Barrett as Oncology Head
|
English | 18.8 KB |
Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Novartis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Novartis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-30 | N/A | Executive member | Sell | None | 1,973,993.83 CHF |
| 2025-03-07 | N/A | Non-Executive member | Buy | None | 160,000.00 CHF |
| 2025-02-11 | N/A | Executive member | Sell | None | 312,203.18 CHF |
| 2025-02-07 | N/A | Executive member | Sell | None | 2,500,278.74 CHF |
| 2025-02-05 | N/A | Executive member | Sell | None | 1,365,687.19 CHF |
| 2025-02-04 | N/A | Executive member | Sell | None | 1,840,201.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 699,424.74 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 698,883.18 CHF |
| 2024-12-19 | N/A | Executive member | Sell | None | 1.00 CHF |
| 2024-11-29 | N/A | Executive member | Sell | None | 167,294.98 CHF |
Peer Companies
